Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

VMware, Inc. (VMW): Did Oracle Corporation (ORCL) Just Signal an Earnings Miss for Red Hat, Inc. (RHT)?

Page 1 of 2

Whenever I come across a stock that is trading at above-average expectations, I get nervous. The situation gets even more nerve-racking when there’s uncertainty in the industry that said company operates. For a while now, this has been the reason that I’ve stayed away from Red Hat, Inc. (NYSE:RHT), a company that I’ve always wanted to like but just can’t. Let me rephrase that: I like the company, I just hate the stock.

VMware, Inc. (NYSE:VMW)

As evident by Red Hat’s price-to-earnings ratio of 68, which is four times that of both Microsoft Corporation (NASDAQ:MSFT) and Oracle Corporation (NASDAQ:ORCL), the Street cares very little about what I think. However, with Red Hat, Inc. (NYSE:RHT)’s fourth-quarter earnings due out on Wednesday, investors would be wise to lower expectations.

Will there be disappointment?
Although the problems of one company are not necessarily the issues of another, if Oracle Corporation (NASDAQ:ORCL)’s disappointing results serve as indication, investors should brace themselves for what Red Hat, Inc. (NYSE:RHT) has to say. Red Hat is coming off an excellent third quarter, during which revenue soared 18.5% year over year. Much of that was due to better-than-expected subscription and services revenue, which grew 19.3%.

Management attributed much of this growth to the company’s Red Hat Enterprise Linux, or RHEL, technologies. However, when looking back at what unfolded, a case can be made that much of the growth was also due to timing. Compare Red Hat’s Q3 performance to that of Oracle. Granted, these two are not often direct competitors, but in terms of the cloud and enterprise software, they compete pretty closely.

First, in Oracle Corporation (NASDAQ:ORCL)’s comparable quarter (Q2), the company posted a 17% surge in software licenses and cloud subscriptions, which (then) topped management’s own bullish projections. However, when looking back at Oracle’s Q1, software licenses and cloud subscriptions had only grown 5%. Oracle’s a great company, yes. But I don’t believe enterprises suddenly realized they needed more cloud services — not to the extent that it should have pushed Oracle Corporation (NASDAQ:ORCL)’s demand 12% from one quarter to the next.

Instead, here’s what happened; corporate budgets were about to expire. This, coupled with uncertainties related to the fiscal cliff, forced companies to accelerate their spending. Oracle was a beneficiary of this. You may consider this a stretch, but the evidence is there. And here’s another hint — why did Oracle’s management guide for a low-end of 3% license growth following a 17% performance?

This indicates that management knew that the 17% surge was abnormal. Unfortunately, even 3% guidance was too high of a target. In the recent quarter, Oracle Corporation (NASDAQ:ORCL) posted a 2% decline in software and cloud subscription revenue, sending the stock plummeting 10%. This tells me that revenue that ordinarily would have arrived in Q3 actually ballooned in Q2. Will it be the same for Red Hat?

Expectations for the quarter?
Red Hat expects Q4 revenue to come in the range of $347 million to $350 million, reflecting a year-over-year increase of 17% to 18%. In this environment, coupled with Oracle’s disappointing results and the soft guidance issued by rival VMware, Inc. (NYSE:VMW), I wouldn’t be surprised if Red Hat were to miss.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!